Browsing Tag
Wegovy
45 posts
Novo Nordisk’s $1.4bn Orbis deal pushes obesity drug race deeper into oral medicines
Novo Nordisk has signed a discovery and licensing agreement worth up to $1.4 billion with Orbis Medicines to develop orally available macrocycle therapies for cardiometabolic disease, extending the Wegovy maker’s strategy beyond injectable GLP-1 drugs and its existing oral semaglutide technology.
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.
Medicare GLP-1 Bridge launches July 1: $50/month Wegovy, Foundayo, Zepbound covered
Medicare GLP-1 Bridge starts today at $50/month. Wegovy, Zepbound KwikPen and Foundayo are in; Ozempic and Mounjaro are out. Novo and Lilly split the win.
Pfizer (PFE) tests investor patience as berobenatide moves toward Phase 3 obesity trials
Find out how Pfizer’s berobenatide data could reshape its obesity drug strategy, GLP-1 competition and investor sentiment today!
Eli Lilly’s oral GLP-1 Foundayo gains new women’s health angle with menopause weight-loss data
Lilly’s oral GLP-1 now targets menopause-linked weight gain. Read why Foundayo could sharpen the next obesity drug battleground.
Magnum Ice Cream (NYSE: MICC) jumps 10.9% on Blackstone and CD&R takeover talk just five months after the Unilever spinoff
Magnum spun out of Unilever at 7.8 billion euros. Froneri sold at 15 billion. Blackstone and CD&R are watching. The summer ice cream season decides the bid.
HLN share price firms as Sensodyne and Centrum drive Haleon’s 2026 organic growth recovery
Sensodyne grows 8%. Centrum targets GLP-1 users. The ÂŁ500m buyback erases shares at sub-340p. Haleon's recovery hinges on Q2 cold and flu normalising.
Diageo (LSE: DGE) gains 1.5% as insider buying and Q3 recovery momentum extend the turnaround narrative
Diageo's 0.3% Q3 growth was minimal. But it was the first positive print in a year, and the August strategy update is where the real test begins.
Novo Nordisk gets UK nod for single-dose Wegovy 7.2mg pen in obesity care
MHRA has approved the single-dose Wegovy 7.2mg pen for adults with obesity in the United Kingdom. Read what it means for patients and Novo Nordisk.
How direct-to-patient delivery could become the next competitive edge in Europe’s GLP-1 race
Read how Novo Nordisk’s Wegovy delivery update could reshape Europe’s GLP-1 competition, pharmacy economics, and patient access strategy.